On Monday, in the course of current trade, Shares of Transocean Ltd. (NYSE:RIG), gained 0.06%, and is now trading at $17.78, as oil prices continued to fall for the third trading day in a row.
WTI crude oil for July delivery was down 0.9% to $59.44 a barrel Monday morning, and Brent crude oil for July delivery was down 1.8% to $62.70 a barrel.
Oil prices were falling Monday as the dollar gained strength due to the debt crisis in Greece and concerns over global oversupply, according to the Wall Street Journal. Analysts said that Saudi Arabia and Libya could soon raise their oil output while Iraq is producing at near-record levels, according to the Journal.
Transocean Ltd., together with its auxiliaries, provides offshore contract drilling services for oil and gas wells worldwide. The company primarily offers deepwater and harsh environment drilling services.
During an Afternoon trade, Shares of Coca-Cola Enterprises Inc. (NYSE:CCE), dipped -0.82%, and is now trading at $43.29.
Coca-Cola Enterprises, talked about its plans and outlook with investors on June 11, at the Deutsche Bank Global Consumer Conference in Paris at 8:45 a.m. EDT (2:45 p.m. CEST).
John F. Brock, chairman and chief executive officer, and Nik Jhangiani, senior vice president and chief financial officer, delivered the remarks.
Coca-Cola Enterprises, Inc. produces, distributes, and markets non-alcoholic beverages in Belgium, continental France, Great Britain, Luxembourg, Monaco, the Netherlands, Norway, and Sweden.
Finally, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), gained 2% Monday.
AVEO Pharmaceuticals, declared that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors.
AVEO recently presented results from the BATON-CRC study, a 265 patient randomized trial exploring the combination of mFOLFOX6 and tivozanib or bevacizumab as first-line treatment in patients with advanced metastatic CRC, at the 2015 American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference. Among the predefined biomarkers explored in this study, neuropilin-1 (NRP-1), a signaling protein known to bind to VEGF-A in serum, was found to be a potential prognostic marker for angiogenesis inhibitor activity and may be predictive of tivozanib activity relative to bevacizumab.
Results from this study and the Company’s ongoing assay development efforts were presented to the FDA. Updated analyses from the Company’s assay development efforts, which are similar to those presented at the AACR conference, will be presented at the forthcoming European Society of Medical Oncology 17th World Congress on Gastrointestinal Cancer taking place July 1-4, 2015 in Barcelona Spain.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
